PTC Therapeutics, Inc.
PTCT· Nasdaq
Released Jul 30, 2026, after the close
10-Q filed Jul 30, 2026, 30 days after period end · 0001070081-26-000017
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $360.52M | $178.88M | $186.70M | $213.81M |
| Net Income | $83.50M | -$64.85M | -$99.18M | -$198.88M |
| EPS Diluted |
PTC Therapeutics, Inc. · CIK 1070081 · Engraved from SEC EDGAR
| $0.92 |
| -$0.83 |
| -$1.29 |
| -$2.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.